We have some exciting news to share! The Motley Fool UK has now become The Twelfth Magpie -- an independent, UK-owned company, led by our long-serving UK management team — Mark Rogers, Chris Nials and Heather Adlington. In practical terms, it’s the same team you know, now fully focused on serving our UK readers and members.

Just as importantly, our approach remains unchanged: long-term, jargon-free, and on your side. This site is our new home, and there will be extra tweaks made across the coming few days as we settle in. So if anything looks a little off, please bear with us!

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

3 Neil Woodford High-Income Blue Chips For Your ISA: GlaxoSmithKline plc, SSE PLC And Legal & General Group Plc

Income seekers should take a look at Woodford picks GlaxoSmithKline plc (LON:GSK), SSE PLC (LON:SSE) and Legal & General Group Plc (LON:LGEN).

| More on:

You’re reading a free article with opinions that may differ from The Twelfth Magpie’s Premium Investing Services. Become a member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn more, and get a free 'Best Buy Now' stock!.

Master equity income investor Neil Woodford knows a thing or two about picking great dividend shares after more than a quarter of a century in the game.

If you’re looking for income ideas for your ISA, GlaxoSmithKline (LSE: GSK) (NYSE: GSK.US), SSE (LSE: SSE) and Legal & General (LSE: LGEN) are three Woodford heavyweight high yielders you may want to consider.

Should you buy Legal & General Group Plc shares today?

Before you decide, please take a moment to review this report first. Despite ongoing uncertainties from US tariffs to global conflicts, Mark Rogers and his team believe many UK shares still trade at substantial discounts, offering savvy investors plenty of potential opportunities to learn about.

That’s why this could be an ideal time to secure this valuable research – Mark’s analysts have scoured the markets to reveal 5 of his favourite long-term ‘Buys’. Please, don’t make any big decisions before seeing them.

GlaxoSmithKline

Big pharma companies have been a feature of Woodford’s funds for most of his career. Despite patent expiries on some blockbuster drugs holding back growth in the industry lately, Woodford reckons the sector “still looks very attractive” for long-term returns for shareholders.

GlaxoSmithKline has been a dividend stalwart over the years. The UK’s top pharma group delivered an 80p a share payout for 2014. At a recent share price of 1,635p, the trailing yield is 4.9% — well above the 3.4% of the FTSE 100 as a whole.

Glaxo has indicated the dividend will be maintained at 80p for 2015. However, the Board also plans to return cash of £4bn (worth another 80p a share or so) to shareholders, following the recent completion of a deal with Swiss group Novartis.

SSE

The UK’s “Big Six” energy companies are currently facing a challenging business environment, an investigation by the Competition and Markets Authority relating to the supply and acquisition of energy, as well as various threats from the Labour Party that could disrupt business and crimp profits.

SSE has said that for its financial year ending 31 March, it intends to raise the dividend in keeping with its policy of increases at least equal to RPI inflation. We could see a payout of 88p, giving a yield of 5.7% at a recent share price of 1,554p.

However, the company expects earnings for the year to come in at about the same level as last year, and says that its ability to increase earnings is “subject to additional risk in 2015/16 and 2016/17”. The dividend may, or may not, come under pressure, but Woodford is sanguine, and has been increasing his holding in SSE in recent months.

Legal & General

There are 15 banks and insurers in the FTSE 100. Woodford is invested in just one: Legal & General. L&G has made a good recovery since the financial crisis, and both earnings and dividends have been rising strongly.

The company hiked the 2014 dividend by 21% to 11.25p, giving a yield of 3.8% at a recent share price of 293p. Now, L&G’s current yield may not be as high as Glaxo’s and SSE’s, but the insurer is set fair for much stronger growth in the next couple of years. Analysts have pencilled in a dividend of 14.5p for 2016, pushing the yield up to close to 5%.

G A Chester has no position in any shares mentioned. The Motley Fool UK has recommended GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Hand of person putting wood cube block with word VALUE on wooden table
Investing Articles

Where should value investors look for stocks in June?

Value investors looking for stocks to buy might be uneasy with artificial intelligence. But other industries look much more attractive…

Read more »

Investing Articles

The latest broker outlooks on Greggs shares look wacky, so what’s happening?

Analyst price targets for Greggs shares are creating some mixed sentiments on where the high-street baker might go next in…

Read more »

Caerphilly Castle, and reflection in the moat.
Investing Articles

2 FTSE 100 dividend stocks that stand out for shareholder returns

Andrew Mackie highlights two FTSE 100 dividend stocks where disciplined capital allocation could continue driving shareholder returns.

Read more »

Senior Adult Black Female Tourist Admiring London
Investing Articles

Just 9% of us can expect a ‘comfortable’ retirement! Could UK shares be the answer?

Millions of Brits could miss out on the retirement of their dreams. Might they avoid this by investing in UK…

Read more »

DIVIDEND YIELD text written on a notebook with chart
Investing Articles

3 passive income shares to consider buying for a 7% yield

Harvey Jones picks out three UK income shares that offer terrific dividends and are trading at tempting valuations. None of…

Read more »

Businessman hand stacking up arrow on wooden block cubes
Investing Articles

How much just £4,160 invested in Rolls-Royce shares 5 years ago is worth now

Rolls-Royce shares have been on a remarkable run of late. Ken Hall takes a look at the key drivers and…

Read more »

Cropped shot of an affectionate young couple posing with a bunch of flowers in their kitchen on their anniversary
Investing Articles

The FTSE 100’s Howden Joinery just made a bold move — should investors care?

Andrew Mackie looks at the FTSE 100’s Howden Joinery and its move into online kitchens, asking what the acquisition means…

Read more »

Queen Street, one of Cardiff's main shopping streets, busy with Saturday shoppers.
Investing Articles

Profits up 173%! Is this surging FTSE small-cap still worth a look?

Ramsdens (LON:RFX) from the FTSE AIM All-Share Index just rose 8%, taking the five-year return above 200%. Why's this under-the-radar…

Read more »